TERT and neoplasm: Immune tumor microenvironment [23, 24], epithelial-mesenchymal transition [25–28], and some peculiar features including BRAFV600E mutation [29], TERT promoter mutations [30, 31], and transcriptomic signatures [32, 33] have been described as predictors of aggressive DTC.